citric acid, anhydrous has been researched along with metformin in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Avizonis, D; Bazile, M; Hashemi, S; Javeshghani, S; Pollak, MN; St Pierre, J; Zakikhani, M | 1 |
| Brereton, I; Chambers, SK; Chow, CW; Coughlin, GD; Doi, SA; Dunglison, NT; Esler, RC; Gardiner, RA; Gianduzzo, TR; Kienzle, N; Lavin, MF; Lu, M; Medcraft, RJ; Oyama, C; Payton, D; Perry-Keene, J; Richards, RS; Roberts, MJ; Samaratunga, H; Schirra, HJ; Yaxley, JW | 1 |
| Ganapathy, V; Higuchi, K; Kopel, J; Ramachandran, S; Ristic, B; Sato, T | 1 |
| Si, Z; Wang, L; Yan, Y; Yuan, W; Zhang, X | 1 |
| Motamedian, E; Mousavi, SM; Naderi, A; Vakilchap, F | 1 |
1 trial(s) available for citric acid, anhydrous and metformin
| Article | Year |
|---|---|
Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol.
Topics: Antigens, Neoplasm; Atorvastatin; Biomarkers, Tumor; Citric Acid; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Metformin; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Research Design | 2016 |
5 other study(ies) available for citric acid, anhydrous and metformin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Alterations in cellular energy metabolism associated with the antiproliferative effects of the ATM inhibitor KU-55933 and with metformin.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Citric Acid; Citric Acid Cycle; DNA-Binding Proteins; Fumarates; HeLa Cells; Hep G2 Cells; Humans; Hypoglycemic Agents; Ketoglutaric Acids; Malates; Membrane Potential, Mitochondrial; Metformin; Morpholines; Oxygen Consumption; Phosphorylation; Protein Serine-Threonine Kinases; Pyrones; Succinic Acid; Tumor Suppressor Proteins | 2012 |
The Hepatic Plasma Membrane Citrate Transporter NaCT (SLC13A5) as a Molecular Target for Metformin.
Topics: Aminoimidazole Carboxamide; Carcinoma, Hepatocellular; Citric Acid; Gene Expression Regulation, Neoplastic; Glycolysis; Hep G2 Cells; Humans; Hypoglycemic Agents; Liver Neoplasms; Metformin; Molecular Targeted Therapy; Ribonucleotides; Signal Transduction; Symporters; TOR Serine-Threonine Kinases | 2020 |
A novel cocrystal of metformin hydrochloride with citric acid: Systematic synthesis and computational simulation.
Topics: Citric Acid; Ethanol; Ligands; Metformin; Methanol; Pharmaceutical Preparations; Solubility; Water | 2022 |
Regulatory-systemic approach in Aspergillus niger for bioleaching improvement by controlling precipitation.
Topics: Aspergillus niger; Citric Acid; Copper; Metformin; Molecular Docking Simulation; Nickel; Oxalic Acid | 2023 |